Answers are grounded in this paper and cite their sources.
Observational analysis improved T cell expansion in tumors, indicating optogenetic strategies may enhance cancer immunotherapy efficacy.
The efficacy of antitumor immunotherapy is closely associated with the expansion of tumor-infiltrating CD8⁺ T cells. However, within the tumor microenvironment, CD8⁺ T cells often exhibit reduced proliferation due to persistent exposure to tumor antigens. The cytokine IL-2 is a potent growth factor that can drive the expansion of tumor-infiltrating lymphocytes. While its clinical application has been severely limited by systemic toxicity and in vivo instability. To address these challenges, we have developed a dual-responsive system (EcNIL-2@UCNP/Gel-CTX) leveraging the hypoxic tropisms of E. coli Nissle 1917(EcN). This system is capable of producing IL-2 in situ upon near-infrared (NIR) irradiation and releasing low-dose cyclophosphamide (CTX) in response to matrix metalloproteinase-2 (MMP-2) in the tumor microenvironment. The EcNIL-2@UCNP/Gel-CTX system not only drives the expansion of CD8⁺ T cells and boost the activity of NK cells but also reduces Treg cell populations, thereby remodeling the immune microenvironment and eliciting robust tumor-specific immune responses in H22 subcutaneous tumors in mice and confers long-term protection against tumor rechallenge by promoting the generation of durable memory T cells. Our findings provide an both light and tumor microenvironment responsive platform for enhanced cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Renjiang Kong (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: